The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia

Journal of Biological Regulators and Homeostatic Agents

Volumn 18, Issue 3-4, 2004, Pages 340-346

  Boonstra, J G ^a   von't Veer, M B ^a   Gratama, J W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

B CLL; CD38; Prognostic marker

Indexed keywords

CD38 ANTIGEN; ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; CD38 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ANTIGEN EXPRESSION; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC ACCURACY; FLOW CYTOMETRY; HUMAN; PREDICTION; PROGNOSIS; REVIEW; CHEMISTRY; MORTALITY;

ADP-RIBOSYL CYCLASE; ANTIGENS, CD; ANTIGENS, CD38; B-LYMPHOCYTES; FLOW CYTOMETRY; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MEMBRANE GLYCOPROTEINS; PROGNOSIS;

EID: 17844363223     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Classification of Tumours. Pathology and Genetics of tumours of the haematopoietic and lymphoid tissues. Lyon: IARCPress, 2001: 127.
2. Houlston R, Catovsky D, Yuille M. Genetic susceptibility to chronic lymphocytic leukemia. Leukemia 2002; 16: 1008-14.
3. Rawstron AC, Yuille MR, Fuller J. Catovsky D, Hillmen P, Houlston RS. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 2002; 100: 2289-90.
4. Marti GE, Carter P, Abbasi F, et al. B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry part B (Clinical Cytometry) 2003; 52B: 1-12.
5. Goldin LR, Ishibe N, Sgambati M, et al. A genome scan of 18 families with chronic lymphocytic leukaemia. Br J Haematol 2003; 121: 866-73.
6. Ghiotto F, Fais F, Valetto A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004; 113: 1008-16.
7. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-34.
8. Rai KR. A critical analysis of staging CLL. In: Gale RP, Rai KR, eds. Chronic lymphoid leukemia: Recent progress and future directions. New York: Alan R. Liss, 1987; 252-62.
9. Binet J-L, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate analysis. Cancer 1981; 48: 198.
10. Call TG, Phyliky RL, Noel P, et al. Incidence of chronic lymphocytic leukemia in Olmsted County Minnesota, 1935 to 1989, with emphasis on changes in initial stage at diagnosis. May Clin Proc 1994; 69: 323-8.
11. Knauf WU, Langenmayer I, Ehlers B, et al. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1997; 27: 523-32.
12. Catovsky D, Fooks J, Richard S, MRC Working Party on Leukemia in Adults. Prognostic factors in chronic lymphocytic leukemia: The importance of age, sex and response to treatment in survival: A report from the MRC CLL 1 trial. Br J Haematol 1989; 72: 141-9.
13. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia. Analysis of its prognostic significance. Br J Haematol 1986; 62: 567-75.
14. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60: 2717-6.
15. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: Integrating molecular insights into clinical practice for patients with CLL. Blood 2004; 103: 1202-9.
16. Keating M, Lerner S, Kantarijan H, Freireich E, O'Brien S. The serum B2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). (Abstract) Blood 1995; 86: 606.
17. Fayad L. Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256-63.
18. Giles FJ, Bekele BN, O'Brien S, et al. A prognostic model for survival in chronic lymphocytic leukemia based on p53 expression. Br J Haematol 2003; 121: 578-85.
19. Molica S, Levato D, Cascavilla N, Levato, L, Musto P. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999; 62: 117-22.
20. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Eng J Med 2000; 343: 1910-6.
21. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: Genomic aberrations and Vh gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993-1007.
22. Damle RN, Wasil T, Fais F, Ghiotto F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-7.
23. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-54.
24. Fais F, Ghiotto, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102: 1515-25.
25. Ritgen M, Lange A, Stilgenbauer S, et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003; 101: 2049-53.
26. Magnac C, Pocher R, Davi F, et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 2003; 17: 133-7.
27. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639-47.
28. Klein U, Tu Y, Stolovitsky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1625-38.
29. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-51.
30. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate marker for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Eng J Med 2003; 348: 1764-75.
31. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 is a more reliable marker of disease progression than immunoglobulin mutation status in chronic lymphocytic leukemia. Blood 2004; 102: 34.
32. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet 2004; 363: 105-11.
33. Jackson DG, Bell JI. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol 1990; 144: 2811-5.
34. Malavasi F, Funaro A, Roggereo S, Horenstein A, Calosso L, Mehta K. Human CD38: A glycoprotein in search of a function. Immunology Today 1994; 15: 95-7.
35. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: An epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 2000; 14: 1079-89.
36. Kramer G, Steiner G, Fodinger D, et al. High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol 1995; 154: 1636-41.
37. Pupilli C, Giannini S, Marchetto P, et al. Autoantibodies to CD38 (ADP-Ribosyl Cyclase/cyclic ADP-Ribose Hydrolase) in Caucasian patients with diabetes. Diabetes 1999; 48: 2309-15.
38. Zupo S, Isnardi L, Megna M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemia's with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996; 88: 1365-74.
39. Zupo S, Rugari E, Dono M, et al. CD38 signalling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells. Eur J Immunol 1994; 24: 1218-22.
40. Jackson DE, Gully LM, Henshall TL, Mardell CE, Marcardle PJ. Platelet endothelial cell adhesion molecule-1 9PECAM-1/CD31) is associated with naïve B-cell phenotype in human tonsils. Tissue Antigens 2000; 56: 105-16.
41. McKenny J, Weiss SW, Folpe AL, Andrew L. CD31 expression in intratumoral macrophages: A potential diagnostic pitfall. Am J Surg Pathol 2001; 25: 116773.
42. Newman PJ. Perspective series: Cell adhesion in vascular biology. J Clin Invest 1997; 99: 3-8.
43. Ibrahim S, Jilani I, O'Brien S, et al. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer 2003; 97: 1914-9.
44. Morabito F, Mangiola M, Stelitano C, Deaglio S, Callea V, Malavasi F. Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B cells: Anecdotal observation or pathogenetic hypothesis for the clinical outcome? Haematologica 2003; 88: 354-6.
45. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immunoglobuline V genes and CD38 expression in CLL. Blood 2000; 95: 2455-6.
46. Damle R, Wasil T, Allen S, Schulman P, Rai KR, Chiorazzi N. Updated data on V gene mutation status and CD38 expression in B-CLL. Blood 2000; 95: 2456-7.
47. Matrai Z, Lin K, Dennis M, et al. CD38 expression and IgVH gene mutation in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 1902-3.
48. Thunberg U, Johnson A, Roos G et al. CD38 expression is a poor predictor for Vh gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001; 97: 1892-3.
49. Ibrahim S, Keating M, Do K-A, et al. CD38 expression as an important prognostic factor in B-cell lymphocytic leukemia. Blood 2001; 98: 181-6.
50. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633-9.
51. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukemia. Br J Haematol 2001; 115: 854-61.
52. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of disease. Blood 2002; 99: 1023-9.
53. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL; clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-84.
54. Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukemia. Br J Haematol 2002; 116: 142-50.
55. Ottaggio L, Viaggi S, Zunino A, et al. Chromosome aberrations evaluated by comparative genomic hybridization in B-cell chronic lymphocytic leukemia: Correlation with CD38. Haematologica 2003; 88: 769-77.
56. Moshynska O, Sankaran K, Pahwa P, Saxena A. Prognostic significance of a short sequence insertion in the MCL-1 promotor in chronic lymphocytic leukemia. J Natl Cancer Inst 2004; 96: 673-82.
57. Matutes E. New additions to antibody panels in the characterization of chronic lymphoproliferative disorders. J Clin Pathol 2002; 55: 180-3.
58. Henderson LO, Marti GE, Gaigalas A, Hannon WH, Vogt Jr RF. Terminology and nomenclature for standardization in quantitative fluorescence cytometry. Cytometry 1998; 33: 97-105.
59. Schwartz A, Marti GE, Poon R, Gratama JW, Fernandez-Repollet E. Standardizing flow cytometry: A classification system of fluoresence standards used for flow cytometry. Cytometry 1998; 33: 106-14.
60. Zenger VE, Vogt R, Mandy F, Schwartz A, Marti GE. Quantitative flow cytometry: Inter-laboratory variation. Cytometry 1998; 33: 138-45.
61. Pannu KK, Joe ET, Iyer SB. Performance evaluation of QuantiBRITE phycoerythrin beads. Cytometry 2001; 45: 250-8.
62. Morabito F, Mangiola M, Oliva B, et al. Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. Leukemia Research 2001; 25: 927-32.
63. Mainou-Fowler T, Dignum H, Taylor PR, et al. Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukemia. Br J Haematol 2002; 118: 755-61.
64. Hsi ED, Kopecky KJ, Appelbaum FR, et al. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukemia. Br J Haematol 2003; 120: 1017-25.
65. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262-9.
66. Pittner BT, Jelinek DF, Kay NE. CLL B cells with a bimodal CD38 expression pattern: Persistence of bimodal populations despite effective therapy for B-CLL. Leukemia 2004; 18: 180-2.
67. D'Arena G, Musto P, Cascavilla N, et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001; 42: 109-14.
68. Domingo-Domenech E, Domingo-Claros A, Gonzales-Barca E, et al. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica 2002; 87: 1021-7.
69. Durig J, Naschar M, Schmucker U, et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002; 16: 30-5.